128 related articles for article (PubMed ID: 37409790)
21. [Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].
Ren J; Yang H; Wang H; Zou J; Lv D; Yu L; Zheng Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Nov; 34(11):1019-1023. PubMed ID: 33254323
[No Abstract] [Full Text] [Related]
22. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
[TBL] [Abstract][Full Text] [Related]
23. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
24. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
25. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
26. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
27. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
30. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
31. Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.
Hyodo M; Nagao A; Asano K; Sakaguchi M; Mizoguchi K; Omori K; Tada Y; Hatakeyama H; Oridate N; Naito K; Iwata Y; Shinomiya H; Hara H; Sanuki T; Yumoto E
Eur J Neurol; 2021 May; 28(5):1548-1556. PubMed ID: 33393175
[TBL] [Abstract][Full Text] [Related]
32. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Socioeconomic Status on Voice Outcomes in Patients With Spasmodic Dysphonia Treated With Botulinum Toxin Injections.
Valenzuela D; Singer J; Lee T; Hu A
Ann Otol Rhinol Laryngol; 2019 Apr; 128(4):316-322. PubMed ID: 30614248
[TBL] [Abstract][Full Text] [Related]
34. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin.
Courey MS; Garrett CG; Billante CR; Stone RE; Portell MD; Smith TL; Netterville JL
Ann Otol Rhinol Laryngol; 2000 Sep; 109(9):819-22. PubMed ID: 11007083
[TBL] [Abstract][Full Text] [Related]
35. Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia.
Leung JS; Rosenbaum A; Holmberg J; Villarroel P; Napolitano C; Badía PI; Lagos-Villaseca A
Auris Nasus Larynx; 2024 Feb; 51(1):106-112. PubMed ID: 37365040
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
37. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
38. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
Yershov D; Partridge R
Prague Med Rep; 2020; 121(2):114-117. PubMed ID: 32553095
[TBL] [Abstract][Full Text] [Related]
39. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
40. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
